Experts from Reflux diagnostic specialists, RD Biomed, discussed the benefits to the NHS of the company’s main product – Peptest, with NHS Medical Director Sir Bruce Keogh at the NHS Innovation Expo in Manchester.
The Hull-based company also met with a delegation from Yorkshire and Humber Academic Health Science Network (AHSN), who they are currently working with to speed up the adoption of Peptest into the NHS.
Peptest is a non-invasive diagnostic solution to detecting reflux disease and associated conditions. Within one patient group alone, those with suspected gastro-oesophageal reflux disease (GORD) who are non-responsive to acid suppression treatment, it has the potential to save the NHS £25 million across England.
The Yorkshire and Humber AHSN has partnered with a number of leading companies in order to assist them in putting their healthcare innovations into practice in clinics and hospitals across the country.
Harvey Dettmar, Managing Director of RD Biomed, said: “We were very pleased to have the opportunity to speak to senior figures from the NHS and discuss the benefits of Peptest. They were all extremely positive about Peptest and its potential from a financial perspective – but more importantly the benefits it presents to the patient. ”
“The GPs I speak to experience frequent cases of patients visiting them with a variety of reflux related symptoms. If Peptest was one of the diagnostic tools available to them, it would allow them to simply give the patient a Peptest and be able to diagnose very quickly if they have reflux. It avoids costly and uncomfortable diagnostic procedures such as endoscopy and oesophageal PH monitoring.”
To find out more about Peptest visit www.peptest.co.uk